BYDUREON (exenatide), antidiabetic

No clinical added value demonstrated in the treatment of type 2 diabetic patients when compared with treatment alternatives

• BYDUREON is a GLP-1 analogue and has Marketing Authorisation in the treatment of type 2 diabetes in combination with metformin, sulfonylureas, metformin and a sulfonylurea, in adults who have not succeeded in adequately controlling their blood sugar levels with the maximum tolerated doses of these oral treatments.
• Its prolonged-release formulation allows for a single weekly subcutaneous injection.
• There was no demonstrable clinical benefit compared with other antidiabetics. It is not possible from the studies to assess how efficacious it is in each of its indications.